The gastrointestinal tract is a therapeutic target for type-2 diabetes. An orally deliverable sucralfate-based material is shown to form a physical coating in the gut, capable of limiting glucose uptake and also administering drugs to the gut lining.
- Yuhan Lee
- Tara E. Deelman
- Jeffrey M. Karp